Corstasis Therapeutics Inc., a biopharmaceutical company specializing in outpatient treatments for cardiovascular and kidney diseases, has announced a strategic partnership with U.S. Heart and Vascular (USHV), a major cardiovascular care organization. This collaboration is designed to enhance outcomes for heart failure patients by creating and refining value-based care pathways that manage fluid overload using ENBUMYST™ (bumetanide nasal spray). The nasal spray provides a new treatment option for individuals with congestive heart failure, liver disease, and chronic kidney disease, allowing them to manage their condition outside of a hospital setting.
Health Technology Insights: Heidi Health Rated High for Reducing Clinician Documentation
Brian Kolski, M.D., Chief Medical Officer at Corstasis Therapeutics, explained that ENBUMYST was developed to give healthcare providers a simple, self-administered option for patients in outpatient settings. He highlighted that the partnership with USHV shows a shared dedication to healthcare innovation and delivering care that is centered around the patient and focused on value.
Health Technology Insights: AllShifts Launches Travel Nurse Staffing for Long-Term Care
The joint effort will involve creating and testing clinical protocols and workflows that match the FDA-approved guidelines for ENBUMYST. These protocols will help ensure that nasal spray diuresis is used at the right time. The partnership also includes training programs for healthcare professionals to support the effective use of this treatment. They plan to gather clinical and economic data to help engage with insurance companies and shape future reimbursement strategies.
Emily Rash, Chief Value-Based Care Officer at USHV, expressed excitement about the collaboration, saying that the organization is always looking for new tools to help doctors and deliver clear benefits to patients and insurers. She believes that offering an outpatient-friendly treatment is a major step forward in managing heart failure in outpatient settings and is proud to be working with Corstasis to bring this innovation to real-world use.
Recently approved by the U.S. Food and Drug Administration, ENBUMYST is used to treat edema caused by congestive heart failure, liver disease, and kidney diseases such as nephrotic syndrome in adults. This partnership positions Corstasis and USHV as leaders in outpatient heart failure care. The goal is to enable earlier treatment, lower the need for hospital stays, and create more efficient care options. Fluid overload from these conditions is a common reason for hospital admissions and readmissions in the United States.
Health Technology Insights: Chris Amery Joins Alliant Insurance Services Northeast Benefits Team
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
